0001209191-20-018258.txt : 20200311 0001209191-20-018258.hdr.sgml : 20200311 20200311190719 ACCESSION NUMBER: 0001209191-20-018258 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200309 FILED AS OF DATE: 20200311 DATE AS OF CHANGE: 20200311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kauffman Michael CENTRAL INDEX KEY: 0001364719 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 20706744 MAIL ADDRESS: STREET 1: C/O KARYOPHARM THERAPEUTICS INC. STREET 2: 85 WELLS AVENUE, SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-658-0600 MAIL ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-09 0 0001503802 Karyopharm Therapeutics Inc. KPTI 0001364719 Kauffman Michael C/O KARYOPHARM THERAPEUTICS INC. 85 WELLS AVENUE NEWTON MA 02459 1 1 0 0 Chief Executive Officer Common Stock 2020-03-10 4 M 0 10000 4.752 A 565122 D Common Stock 2020-03-10 4 S 0 7932 22.1086 D 557190 D Common Stock 2020-03-10 4 S 0 2068 22.6405 D 555122 D Common Stock 2020-03-09 4 M 0 10000 4.752 A 766489 I By Spouse Common Stock 2020-03-09 4 S 0 7000 22.5791 D 759489 I By Spouse Common Stock 2020-03-09 4 S 0 3000 22.3803 D 756489 I By Spouse Stock Option (right to buy) 4.752 2020-03-10 4 M 0 10000 0.00 D 2023-09-02 Common Stock 10000 366061 D Stock Option (right to buy) 4.752 2020-03-09 4 M 0 10000 0.00 D 2023-09-02 Common Stock 10000 410303 I By Spouse These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.57 to $22.55, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.575 to $22.76, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.095 to $23.04, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.05 to $23.75, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter. /s/Christopher B. Primiano, Attorney-in-Fact for Michael Kauffman 2020-03-11